Catalysts / WHWK
Upcoming FDA decisions and readouts we track for Whitehawk Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Whitehawk Therapeutics (WHWK, listed on Nasdaq). They cover 2 programmes: HWK-007 (EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer) and HWK-016 (Advanced ovarian and endometrial cancers).
First on the list: the Phase 1 readout for HWK-007 (EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer), guided by the company to H1 2027. By stage, the upcoming rows are 2 Phase 1 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics WHWK · Nasdaq | HWK-007 | EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Whitehawk Therapeutics WHWK · Nasdaq | HWK-016 | Advanced ovarian and endometrial cancers | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList